Zhuonan Zhuang

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Jianhua Ling · 3 shared papers, 2016–2017 · strength 0.16
   • Paper NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation. DOI 10.1016/j.canlet.2017.09.018↗
   • Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
   • Paper IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. DOI 10.1158/1078-0432.ccr-14-3382↗
2. Huai‐Qiang Ju · 3 shared papers, 2016–2017 · strength 0.16
   • Paper NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation. DOI 10.1016/j.canlet.2017.09.018↗
   • Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
   • Paper IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. DOI 10.1158/1078-0432.ccr-14-3382↗
3. Jie Fu · 3 shared papers, 2016–2017 · strength 0.16
   • Paper NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation. DOI 10.1016/j.canlet.2017.09.018↗
   • Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
   • Paper IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. DOI 10.1158/1078-0432.ccr-14-3382↗
4. Paul J. Chiao · 3 shared papers, 2016–2017 · strength 0.16
   • Paper NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation. DOI 10.1016/j.canlet.2017.09.018↗
   • Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
   • Paper IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. DOI 10.1158/1078-0432.ccr-14-3382↗
5. Lu Yu · 2 shared papers, 2017 · strength 0.11
   • Paper NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation. DOI 10.1016/j.canlet.2017.09.018↗
   • Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
6. Xiaoqiang Fan · 2 shared papers, 2016 · strength 0.10
   • Paper Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis. DOI 10.1371/journal.pone.0149028↗
   • Paper IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. DOI 10.1158/1078-0432.ccr-14-3382↗
7. Long Peng · 1 shared paper, 2016 · strength 0.05
   • Paper Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis. DOI 10.1371/journal.pone.0149028↗
8. Lifeng Yang · 1 shared paper, 2017 · strength 0.05
   • Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
9. Huamin Wang · 1 shared paper, 2017 · strength 0.05
   • Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
10. Jun Yao · 1 shared paper, 2017 · strength 0.05
    • Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
11. Haoqiang Ying · 1 shared paper, 2017 · strength 0.05
    • Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
12. Ronald Anthony Depinho · 1 shared paper, 2017 · strength 0.05
    • Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
13. Rui‐Hua Xu · 1 shared paper, 2017 · strength 0.05
    • Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
14. Mien‐Chie Hung · 1 shared paper, 2017 · strength 0.05
    • Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
15. Deepak Nagrath · 1 shared paper, 2017 · strength 0.05
    • Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
16. Peng Huang · 1 shared paper, 2017 · strength 0.05
    • Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
17. Min Li · 1 shared paper, 2016 · strength 0.05
    • Paper IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. DOI 10.1158/1078-0432.ccr-14-3382↗
18. Jason B. Fleming · 1 shared paper, 2016 · strength 0.05
    • Paper IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. DOI 10.1158/1078-0432.ccr-14-3382↗
19. Davide Melisi · 1 shared paper, 2016 · strength 0.05
    • Paper IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. DOI 10.1158/1078-0432.ccr-14-3382↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.